Cellectis
Cellectis
cellectis.com

Locations

Europe · Paris, France · Île-de-France, France

industry

Biotechnology · DeepTech · Health

Size

201-1000 employees

Stage

Other

founded in

1999

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Something looks off?
Open jobs at Cellectis
Powered by Getro